LY294002

製品コードS1105 別名:SF 1101, NSC 697286

LY294002化学構造

分子量(MW):307.34

LY294002は初めての周知されたPI3Kα/δ/βを抑制する小分子で、無細胞試験でIC50値が0.5 μM/0.57 μM/0.97 μM に分かれることですが、溶液にの状態はWortmanninにの状態よりもっと安定になりって、自食体の形成も遮断できます。

サイズ 価格(税別)  
JPY 31722.00
JPY 24402.00
JPY 44820.00
JPY 127820.00

文献中の使用例(72)

カスタマーフィードバック(14)

  • Type I IFNs induce ISG expression in a serine phosphorylation-independent manner. Cells were treated with kinase inhibitors (SB203580, rottlerin, Ly294002, PD98059, and SP600125) before stimulation with IFN-a and IFN-b for 6 hours. Cell lysates were used in western blotting and probed for serine phosphorylation.The relative amounts of pSTAT1 S727 in (up-graph) were quantied and normalized to an untreated control (below-graph).

    Hepatology 2014 59(4), 1262-72. LY294002 purchased from Selleck.

    different signal-inhibitory profile by applying 120 nmol/L BGT226, 20 μmol/L LY294002, or 100 nmol/L rapamycin in FaDu cells.

    Clin Cancer Res 2011 17, 7116-7126. LY294002 purchased from Selleck.

  • Stimulation response of p37d-expressing cells. (c) Western blot of 5 min serum stimulated HEK-293 cells stably expressing p37d, p110d or control, with the presence of inhibitors as indicated at the top.

    Oncogene 2012 31, 3277–3286. LY294002 purchased from Selleck.

    PTEN transfection or inhibition of the PI3K-AKT and IGF-1R signaling pathways increases the trastuzumab sensitivity of NCI-N87/TR cells. After treating the cells with a PI3K inhibitor (LY294002), the expression of AKT and P-AKT proteins was assessed by Western blotting. Tubulin expression indicated equal loading. All gels run under the same experimental conditions and the experiments were repeated 3 times. The representative images were cropped and shown. Control: cells without any treatment.

    Sci Rep 2015 5, 11634. LY294002 purchased from Selleck.

  • SCC61 or Detroit 562 xenografted tumors respond to treatment by PI3K inhibitor, LY294002 alone, or in combination with gefitinib. % tumor growth is shown. By two-way ANOVA, the effect of treatment and time is considered significant;

    Mol Oncol 2013 7, 359-68. LY294002 purchased from Selleck.

    Inhibition of EGFR and PI3K/AKT pathway has additive effects in SCCHN cell lines with constitutively active PIK3CA mutations, while removing negative regulation of PI3K/AKT pathway increases resistance in sensitive SCCHN cell line. A, results from MTT assays on cells treated with PI3K inhibitor, LY294002, and gefitinib.

    Mol Oncol 2013 7, 359-68. LY294002 purchased from Selleck.

  • Lyn-PI3K-BTK signaling is required for the inhibitory effect of anti-CD180 on the activation of IFN-α signaling. (a and b) Isolated murine splenic B220+ B cells were pretreated with dasatinib (5 μM), a Lyn inhibitor; LY294002 (5 μM), a PI3K inhibitor; ibturinib (1 μM), a BTK inhibitor; enzastaurin (1 μM), a PKC β inhibitor; U0126 (3 μM), an ERK inhibitor; SP600126 (2 μM), a JNK inhibitor or SB20358 (1 μM), a p38 inhibitor for 1 h, followed by stimulation with anti-CD180 antibody (0.2 μg/mL) or mouse IFN-α (1000 U/mL) for 4 h. qPCR analysis of the expression of IFIT1 (a) and MX1 (b). (c) Isolated murine splenic B220+ B cells were pretreated with dasatinib (5 μM), LY294002 (5 μM), and ibturinib (1 μM) for 1 h, followed by stimulation with anti-CD180 antibody (0.2 μg mL−1) or mouse IFN-α (1000 U mL−1) for 40 min. Western blot analysis of the phosphorylation level of STAT-2. The data shown represent the mean values of three independent experiments, and the error bars represent the SEM. *p < 0.05, **p < 0.01, ***p < 0.001, as determined by ANOVA; ns denotes p > 0.05.

    Cell Mol Immunol, 2017, 14(2):192-202. LY294002 purchased from Selleck.

    Immunofluorescence and flow cytometric analyses of the translocation of ABCG2 in MCF-7 FLV1000 cells before and after treatment with the PI3K inhibitor LY294002. Confocal microscopy of MCF-7 FLV1000 cells after a 16-h treatment with 2 uM or 4 uM of LY294002 was performed as described in Figure.

    Br J Pharmacol 2013 70(5), 1137-51. LY294002 purchased from Selleck.

  • IGF1 increases apical fibronectin in late stage blastocysts. Representative confocal images of blastocysts stained for fibronectin (Green) and DAPI (Blue). Day 5 blastocysts were cultured in SS medium for 24 (A and B), 48 (C and D) or 72 h (E-H) in the absence (A, C and E) or presence (B, D and F) of 10 ng/ml IGF1 or in the presence of a PI3 Kinase inhibitor (5 uM LY294002 + 10 ng/ml IGF1) (G) or in the presence of 10 ng/ml IGF1, attached to a coverslip (H). Scale bars represent 20 mm. Red line indicates location of coverslip. Arrow indicates location of the inner cell mass (ICM). The following total number of blastocysts were analysed, from at least 3 experimental repeats in each treatment; 24 in the SS group (24 h), 21 in SS plus IGF1 (24 h), 26 in SS (48 h), 30 in SS plus IGF1 (48 h), 40 in SS (72 h), 59 in SS plus IGF1 (72 h), 13 in SS plus IGF1 + LY294002 (48 h) and 15 blastocysts were analysed that were attached to a coverslip (72 h).

    Hum Reprod 2015 30(2), 284-98. LY294002 purchased from Selleck.

    Inhibition of PI3K, ERK and mTOR prevents the activation of S6K1 and S6 induced by suppression of PKD1 activity. A549 cells were incubated in the absence (-) or presence of either 5 uM Kb or 5 uM Kb and 20 uM LY294002 or 5 uM Kb and 10 uM BKM120 (as indicated) for 1 h prior to stimulation of cells with 50 nM PMA for 30 min and 1 h.

    Int J Biochem Cell Biol 2015 60, 34-42. LY294002 purchased from Selleck.

  • We treated all of drugs in T47D which has a PI3KCA H1044R mutation with the concentration shown below for 1 hour and performed western blot analysis using antibodies to phospho-AKT(SERINE 472), and total AKT.

     

     

    2010 Saraswati Sukumar of Johns Hopkins University School of Medicine. LY294002 purchased from Selleck.

    T47Dcells were pretreated with 100 ng/ml EGF for 20 min and then treated with the indicated concentrations of LY294002 for 24 hours.

     

     

    2010 Dr. Zhang of Tianjin Medical University. LY294002 purchased from Selleck.

  • Comparative effects of inhibitors by immunofluorescence microscopy study. Confluent HC11 cells were grown on poly-L-lysine-coated glass coverslips (immunofluorescence) and on plastic plates (biochemical control) and then treated with inhibitors according to the standard procedure. Upper part: the biochemical action of the inhibitors was tested to validate the immunofluorescence results. Cellular proteins were analyzed by SDS-PAGE and the immunoblots were successively probed with anti-ADRP, anti-β-casein, and anti- β-actin antibodies and their respective HRP-conjugated secondary antibodies. Each experimental condition was performed in duplicate. Lower part: cells were fixed, permeabilized and subjected to immunofluorescence microscopy using antiserum against ADRP and TRITC-conjugated secondary antibody (red).

    Biochim Biophys Acta 2012 1823(5), 987-96. LY294002 purchased from Selleck.

    Comparative effects of wortmannin and LY294002 on ADRP and β -casein synthesis. Con fluent HC11 cells were treated according to the standard procedure in the absence or presence of 4 ng/ml EGF either with or without 100 nM wortmannin or 50μM LY294002. Cellular proteins were analyzed by SDS-PAGE and immunoblot successively probed with anti-ADRP, anti-β-casein, anti-β -actin antibodies and their respective HRP-conjugated secondary antibodies. ECL signals were quantified by densitometry and normalized to β-actin. Each experimental condition was performed in triplicate. Percentages of inhibition for both inhibitor and hormonal treatments are indicated in the text.

    Biochim Biophys Acta 2012 1823(5), 987-96. LY294002 purchased from Selleck.

製品安全説明書

PI3K阻害剤の選択性比較

生物活性

製品説明 LY294002は初めての周知されたPI3Kα/δ/βを抑制する小分子で、無細胞試験でIC50値が0.5 μM/0.57 μM/0.97 μM に分かれることですが、溶液にの状態はWortmanninにの状態よりもっと安定になりって、自食体の形成も遮断できます。
ターゲット
p110α [1]
(Cell-free assay)
p110δ [1]
(Cell-free assay)
p110β [1]
(Cell-free assay)
0.5 μM 0.57 μM 0.97 μM
体外試験

LY294002 inactivates Akt/PKB, consequently inhibiting cell proliferation and inducing apoptosis. LY294002 demonstrates a remarkable growth-inhibitory and apoptosis-inducing effect in these colon cancer cell lines, with decreased expression of phosphorylated Akt (Ser473). [2]LY294002 induces marked nuclear pyknosis and diminished cytoplasmic volume in the tumor cells. Thus, LY294002 markedly inhibits ovarian cancer cell proliferation in vitro. LY294002 induces specific G1 arrest in cell growth, leading to almost complete inhibition of melanoma cell proliferation and partial inhibition of MG-63 (osteosarcoma cell line) proliferation. The effect of LY294002 on cell cycle progression may provide insights into a possible link between the PI3K activation pathway and cancer cell cycle regulation. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MDA-MB-231 cells MnXzR4VtdCCrbo\hd4lwdiCjc4PhfS=> MoXGNlQhcA>? NFHHbVNKdmirYnn0bY9vKG:oIHXwbZRp\WyrYXyg[5Jwf3SqIH\hZ5Rwei2rbnT1Z4VlKGOnbHygcYloemG2aX;uJI9nKGi3bXHuJG1FSS2PQj2yN|Eh[2WubIOgdJJmNWmwY4XiZZRm\CCob4KgNlQhcHK|IHL5JINmdGxiaX72ZZNqd25iYYPzZZktKEmFNUC9NE4{QCEQvF2u NXjFO5p[OjJ6MESxNFg>
Sf21 cells M3\RN2Z2dmO2aX;uJIF{e2G7 NH:wfotKdmirYnn0bY9vKG:oIH3veZNmKHerbHSgeJlx\SCSSUPLZYxxcGFiZYjwdoV{e2WmIHnuJHNnOjFiY3XscJMh[29vZYjwdoV{e2mwZzDOMZRmem2rbnHsJGhqey22YXfn[YQhcHWvYX6gdFg2[SC3c3nu[{BNNWGucHjhMZBpd3OyaHH0bYR6dGmwb4PpeI9tKHO3YoP0doF1\SCkeTDUUGMh[mG|ZXSgdIhwe3Cqb4KgbY1i\2mwZzygTWM2OD1yLkWg{txO NEWxZZozOjV{ME[zNC=>
Sf21 cells NEfY[WJHfW6ldHnvckBie3OjeR?= MWDJcohq[mm2aX;uJI9nKG2xdYPlJJJm[2:vYnnuZY51KFCLM1vhcJBp[SCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMucW6oZXP0[YQhW2Z{MTDj[YxteyxiSVO1NF0xNjVizszNMi=> M2nab|E6PzR6Mk[5
Sf9 cells MnvzSox2d3Knc3PlcpQheG:uYYLpfoF1cW:wIHHzd4F6 NXnsTYtwUW6qaXLpeIlwdiCxZjDoeY1idiCSSUPLZYxxcGFiZYjwdoV{e2WmIHnuJHNnQSClZXzsd{BjgSCobIXvdoV{[2WwdDDwc4xiemm8YYTpc44h[XO|YYmsJGlEPTB;MD61OUDPxE1w NIf2NXAzOTF{MU[zNS=>
THP1 cells MlXmSpVv[3Srb36gZZN{[Xl? MWPJcohq[mm2aX;uJI9nKFOFRkGtbY5lfWOnZDDQT2IwSWu2IIDoc5NxcG:{eXzheIlwdiCrbjDUTHAyKGOnbHzzMEBKSzVyPUGuNFEh|ryPLh?= MVWxOlc5QTd2Mh?=
human PC3 cells MVPGeY5kfGmxbjDhd5NigQ>? NHfBcGc{OCCvaX6= NWjZTZQ3UW6qaXLpeIlwdiCxZjDQTVNMKGmwIHj1cYFvKFCFMzDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG|ZTDpckBCU1RicHjvd5Bpd3K7bHH0bY9vKGG2IIPldolv\SB2N{OgZYZ1\XJiM{CgcYlveyCkeTDFUGlUSSxiSVO1NF0yNjQQvF2u MV2yN|QyODByNR?=
HeLa (human carcinoma) cells. M4D5ZmZ2dmO2aX;uJIF{e2G7 MmXaTY4hfmm2cn:gbY5pcWKrdHnvckBw\iCGTlGt[IVx\W6mZX70JJBzd3SnaX6gb4lv[XOnKFTORU1RUyliZoLvcUBJ\UyjIDjoeY1idiClYYLjbY5wdWFrIHPlcIx{NCCLQ{WwQVEvPCEQvF2u NWTsfJVWOTV4NUi4O|A>
THP1 cells NEPRSIxHfW6ldHnvckBie3OjeR?= M{fuXmlvcGmkaYTpc44hd2ZiTVPQNU1qdmS3Y3XkJHBMSi:Da4SgdIhwe3Cqb4L5cIF1cW:wIHnuJHRJWDFiY3XscJMtKEmFNUC9NU43PSEQvF2u M4DsT|E3Pzh7N{Sy
HeLa cells MYfGeY5kfGmxbjDhd5NigQ>? NVnQNZF{UW6qaXLpeIlwdiCxZjDtWG9TKHC{b4TlbY4hcXOxbHH0[YQh\nKxbTDI[WxiKGOnbHzzMEBKSzVyPUKuOUDPxE1w MWSxOVY2QDh5MB?=
human MCF7 cells MmPqR5l1d3SxeHnjxsBie3OjeR?= MnTGR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{BqdiCycnXz[Y5k\SCxZjCyNEDPxE1iY3jsc5JweXWrbnWgZpkhW1KEIHHzd4F6NCCJSUWwQVIvPjNizszNMi=> MYSxPFY6OTh7NB?=
HeLa cells NVW4R|BRTnWwY4Tpc44h[XO|YYm= M3PIcWlvcGmkaYTpc44hd2ZiQWitO|UxOyCkaX7kbY5oKHSxIILlZ49u[mmwYX70JHBtczNiZYjwdoV{e2WmIHnuJGhmVGFiY3XscJMh[nliV3XzeIVzdiCkbH;0MEBKSzV;MzFOwG0v NH7MTI0yPzF|NUK0PC=>
human MCF7 cells NV;lbYNmS3m2b4TvfIlkyqCjc4PhfS=> NG\D[WZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGmwIIDy[ZNmdmOnIH;mJFExKHWPIHPocI9zd3G3aX7lJIJ6KFOUQjDhd5NigSxiR1m1NF0{NjB6IN88UU4> M2XqbFE5PjlzOEm0
human MCF7 cells NXjKWWhGS3m2b4TvfIlkyqCjc4PhfS=> MYfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIJ6KFOUQjDhd5NigSxiR1m9N{4yPiEQvF2u MYexPFY6OTh7NB?=
human MDA-MB-231 cells Mn;1R5l1d3SxeHnjxsBie3OjeR?= NVX4fG1oS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{BqdiCycnXz[Y5k\SCxZjCyNEDPxE1iY3jsc5JweXWrbnWgZpkhW1KEIHHzd4F6NCCJSU2zMlMzKM7:TT6= NVT5VFFqOTh4OUG4PVQ>
human MDA-MB-231 cells MoLWR5l1d3SxeHnjxsBie3OjeR?= NYDH[FIyS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{BqdiCycnXz[Y5k\SCxZjCxNEB2VSClaHzvdo9yfWmwZTDifUBUWkJiYYPzZZktKEeLNUC9OE4{PSEQvF2u MXWxPFY6OTh7NB?=
human MDA-MB-468 cells MWrDfZRwfG:6aXRCpIF{e2G7 NHuwVI1EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtOFY5KGOnbHzzJIlvKHC{ZYPlcoNmKG:oIEKwJJVOKGOqbH;yc5F2cW6nIHL5JHNTSiCjc4Phfg+9lCCLQ{WwQVQvPzZizszNMi=> MYSxPFY6OTh7NB?=
human HCT116 cells NIfHU3VIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXzjc2dXPDhiaB?= MV3Hdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDIR3QyOTZiY3XscJMhd3[ncnX4dJJme3OrbnegVGk{U2GucHjhJGgyODR5UjDteZRidnRiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF02NjNizszN M1q1b|IzOjF{N{Kx
human HCT116 cells M2KzNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MV20PEBp MXLHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME21Mlgh|ryPLh?= M17Fc|IzOjF{N{Kx
HeLa cells Mn3qRolv\GmwZzDh[oZqdmm2eTDhd5NigQ>? NYjqTVZMSmmwZHnu[{Bi\m[rbnn0fUBnd3JiUFmzMYtqdmG|ZTDpd49t[XSnZDDmdo9uKEinTHGgZ4VtdHNuIFvpQVYh|ryP MVSxOVY2QDh5MB?=
human HCT116 cells M3vPN2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHK0eXA1QCCq NVTDXWRqT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hUEOWMUG2JINmdGy|IH;2[ZJmgHC{ZYPzbY5oKFCLM1vhcJBp[SCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVYvPyEQvF2u M1ThNlIzOjF{N{Kx
MDA-MB-231 cells NX7vTJF1S3m2b4TvfIlkyqCjc4PhfS=> NGK3UY1EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIJ6KFOUQjDhd5NigSxiR1m1NF03NjdzIN88UU4> NXzw[WU3OTh4OUG4PVQ>
Sf9 cells MYDGeY5kfGmxbjDhd5NigQ>? NUDTOVltUW6qaXLpeIlwdiCxZjDDT|Ih\XiycnXzd4VlKGmwIGPmPUBk\WyuczygTWM2OD14Lkmg{txONg>? NXTDUYNPOTh|MkG3NVY>
human U87MG cells NGDydYJHfW6ldHnvckBie3OjeR?= MUXJcohq[mm2aX;uJI9nKEeVS{OtZoV1[SCrbjDoeY1idiCXOEfNS{Bk\WyuczDifUBGVEmVQTygTWM2OD16LkGg{txONg>? NF[0cXMyQDN2NU[wPS=>
human MDA-MB-468 cells NYfiSYN2S3m2b4TvfIlkyqCjc4PhfS=> MlzFR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUS2PEBk\WyuczDpckBxemW|ZX7j[UBw\iBzMDD1UUBkcGyxcn;xeYlv\SCkeTDTVmIh[XO|YYmsJGdKPTB;OD6yJO69VS5? MlrENVg3QTF6OUS=
human A375 cells Ml\zVJJwdGmoZYLheIlwdiCjc4PhfS=> NICwTIg1PiCq MmfsRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCDM{e1JINmdGy|IHHmeIVzKDR4IHjyd{whUUN3ME24MlQh|ryPLh?= NHTwSHoyPzB2OUK0PC=>
human A375 cells MnvUVJJwdGmoZYLheIlwdiCjc4PhfS=> M3PyOGlvcGmkaYTpc44hd2Zic3XyeY0ucW6mdXPl[EBxem:uaX\ldoF1cW:wIH;mJIh2dWGwIFGzO|Uh[2WubIOsJGlEPTB;OD60JO69VS5? M3Xm[|E4PjBzN{O5
human HL60 cells NXfye4FSS3m2b4TvfIlkyqCjc4PhfS=> MnfzO|IhcA>? MV;DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;OT65OEDPxE1w MknqNlI1QDB6NUG=
mouse Raw264 macrophage MkD2SpVv[3Srb36gZZN{[Xl? M4LMZmlvcGmkaYTpc44hd2ZiQ{XhMY1m\GmjdHXkJHBMSi:Da4SgdIhwe3Cqb4L5cIF1cW:wIHnuJI1wfXOnIGLhe|I3PCCvYXPyc5Bp[WenLDDJR|UxRTFyIN88UU4> MX2xOlc5QTd2Mh?=
Sf9 cells MmrSSpVv[3Srb36gZZN{[Xl? Mnf6TY5pcWKrdHnvckBw\iCKaYOteIFo\2WmIHLveolv\SCSSUPLJIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNuIFnDOVA:OTBizszNMi=> M2HtOVExQTl6M{Wx
human MDA-MB-468 cells M2jLbmN6fG:2b4jpZ:Kh[XO|YYm= NWDifGZ4S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVQ3QCClZXzsd{BjgSCVUlKgZZN{[XluIFnDOVA:OTBwNDFOwG0v MXKxPFY6OTh7NB?=
human PC3 cell M4G2RnBzd2yrZnXyZZRqd25iYYPzZZk> M{nJOlczKGh? MlnHTY5pcWKrdHnvckBw\iCqdX3hckBRSzNiY3XscEBxem:uaX\ldoF1cW:wIHHmeIVzKDd{IHjyd{BjgSC|cHXjeJJweGixdH;t[ZRzcWNiYX7hcJl{cXNuIFnDOVA:OTJwMTFOwG0v MWWyN|QyODByNR?=
human HL60 cells M4G3THBzd2yrZnXyZZRqd25iYYPzZZk> NHzjO444OiCq Mn\RRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKTE[wJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiYXLzc5Jj[W6lZTDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTF6LkSzJO69VS5? MVKyOVY6Ozd6Nx?=
human BT474 cell NHrFRZVRem:uaX\ldoF1cW:wIHHzd4F6 NYfufHN[PzJiaB?= M2XKdWlvcGmkaYTpc44hd2ZiaIXtZY4hSlR2N{SgZ4VtdCCycn;sbYZmemG2aX;uJIFnfGW{IEeyJIhzeyCkeTDzdIVkfHKxcHjveI9u\XS{aXOgZY5idHm|aYRvwKwhUUN3ME2yNE44KM7:TT6= NXzJOm54OjN2MUCwNFU>
THP1 cells MWHGeY5kfGmxbjDhd5NigQ>? NWfXcJJlUW6qaXLpeIlwdiCxZjDNR3AyNWmwZIXj[YQh[2inbX;0ZZhqeyCxZjDUTHAyKGOnbHzzMEBKSzVyPUO3JO69VS5? MkXiNVY4QDl5NEK=
human 184B5 cells NIP1dnlEgXSxdH;4bYPDqGG|c3H5 NFHyWFJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckAyQDSENTDj[YxteyCkeTDTVmIh[XO|YYmsJGdKPTB;M{muN|ch|ryPLh?= NGXQUXgyQDZ7MUi5OC=>
human KB cells M4fId2N6fG:2b4jpZ:Kh[XO|YYm= MmTOO|IhcA>? MmDtR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT2Ih[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD12ND63OkDPxE1w NV3vfm15OjF7NEWyOVA>
mouse RAW264.7 cells MXjGeY5kfGmxbjDhd5NigQ>? NFjPdHozPSEQvF2= MUeyNEBp MlTsTY5pcWKrdHnvckBw\iCSSUPLM2FMXCCrbjDtc5V{\SCUQWeyOlQvPyClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGxRWy2rbnT1Z4VlKGmQT2OgdJJwfGWrbjDlfJBz\XO|aX;uJIF1KDJ3IN88UUBi\nSncjCyNEBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{ MnfSNlQzQTl4MU[=
human A2780 cells NITPWYZCeG:ydH;zbZMh[XO|YYm= NETvbG4zKM7:TR?= NYDsNHRFOTJiaB?= NI\5TpdKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m|IHnuJINqe3CuYYTpck1z\XOrc4ThcpQhcHWvYX6gRVI4QDBiY3XscJMh[XO|ZYPz[YQh[XNiZHXjdoVie2ViaX6gdIhwe3Cqb4L5cIF1\WRiQXv0JIxmfmWuIHH0JFIhfU1iYX\0[ZIhOTJiaILzJIJ6KGmvbYXuc4Jtd3RiYX7hcJl{cXNw NWqxZmVmOTd4OESwNVg>
human SW480 cells NYPDN4hHTnWwY4Tpc44h[XO|YYm= MUmyNEDPxE1? M3;wU|I1KGh? NXuzWFF7TGWlcnXhd4UhcW5ic4Xyeol3cW5iZYjwdoV{e2mxbjDpckBpfW2jbjDTW|Q5OCClZXzsd{BifCB{MDD1UUBi\nSncjCyOEBpenNiYomgbY1ufW6xYnzveEBidmGueYPpdy=> MWOxO|Q4Ojl4Mh?=
mouse mast cells MWPGeY5kfGmxbjDhd5NigQ>? NUPHZZpKOjBizszN M4XvV2lvcGmkaYTpc44hd2ZiU1PGMYlv\HWlZXSgVGtDN0GtdDDwbI9{eGixconsZZRqd25iaX6gcY92e2VibXHzeEBk\WyuczDheEAzOCEQvF2= NYHLZmdFOTZ5OEm3OFI>
human BJ cells MmjlSpVv[3Srb36gZZN{[Xl? NHzEV|AzPSEQvF2= NFjhfYczKGh? NVzoNYtQUW6qaXLpeIlwdiCxZjDQTVNMKHOrZ37hcIlv\yCrbjDQSGdHNXO2aX31cIF1\WRic3XyeY0he3Sjco\l[EBpfW2jbjDCTkBk\WyuczD0doFve2[nY4Tl[EB4cXSqIIDsZZNucWRiRVfGVE9RUCCmb33hbY4hd2ZiQXv0JIF{e2W|c3XkJIF{KHO3cIDy[ZN{cW:wIH;mJHBJNUWJRmCgdoVlcXO2cnnieZRqd25idH:gdIxie22jIH3lcYJz[W6nIHH0JFI2KHWPIITy[YF1\WRiMjDodpMh[mWob4LlJHBFT0ZiY3jhcIxmdmenIHL5JINwdm[xY3HsJI1q[3Kxc3PvdJk> MYKxOlc3PzB6NR?=
human IGROV1 cells NHjEfYZHfW6ldHnvckBie3OjeR?= Mkf6NlQwPDhiaB?= NGLxeI1KdmirYnn0bY9vKG:oIGDJN2swSWu2IHnuJIh2dWGwIFnHVm9XOSClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDwbI9{eGixconsZZRm\CCDS2SgcIV3\WxiYYSgNUB1dyB3IITpcYV{KEmFNUCgZYZ1\XJiMkSgeI8hPDhiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?= NHeyWmMzOTJzNkG1NS=>
human IGROV1 cells MliwSpVv[3Srb36gZZN{[Xl? NVvm[VJROjRxNEigbC=> M4jIWmlvcGmkaYTpc44hd2ZiUFmzT{9Cc3RiaX6gbJVu[W5iSVfSU3YyKGOnbHzzJIF{e2W|c3XkJIF{KGSnY4LlZZNmKGmwIHP5Z4xqdiCGMTDs[ZZmdCCjdDCxJJRwKDVidHnt[ZMhUUN3MDDh[pRmeiB{NDD0c{A1QCCqcoOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| Mnf2NlEzOTZzNUG=
rat RBL2H3 cells NXrmSJVkTnWwY4Tpc44h[XO|YYm= MoXDTY5pcWKrdHnvckBw\iCDMkOxPFcucW6mdXPl[EBl\We{YX71cIF1cW:wIHnuJJJifCCUQlyyTFMh[2WubIO= NGXEWIEyQDN{OEexOi=>
human BJ cells NWjielJlTnWwY4Tpc44h[XO|YYm= NXrMOHkyOjVizszN NWPHe5J{OiCq M3W4O2FkfGm4YYTpc44hd2ZiQXv0JJBpd3OyaH;yfYxifGmxbjDheEBVcHJ|MEigbY4hWESJRj3zeIlufWyjdHXkJJNmenWvIIP0ZZJ3\WRiaIXtZY4hSkpiY3XscJMh[XRiMkWgeW0hfHKnYYTl[EAzKGi{czDi[YZwemViUFTHSkBkcGGubHXu[4Uh[nliaX3teY5w[myxdITpcoc> MUSxOlc3PzB6NR?=
human HCT116 cells MoXuSpVv[3Srb36gZZN{[Xl? M{jUS|ExKM7:TR?= NU\oWZU3OTBibXnu MlfpTY5pcWKrdHnvckBw\iCSSUPLZYxxcGFiaX6gbJVu[W5iSFPUNVE3KGOnbHzzJJV{cW6pIGuzNnBeSVSSIHH0JFExKHWPIHHmeIVzKDFyIH3pcpM> MmixNlIzOTJ5MkG=
human HCT116 cells MUHGeY5kfGmxbjDhd5NigQ>? M4\IflExKM7:TR?= NHH2ZnkyOCCvaX6= NHPBbW9KdmirYnn0bY9vKG:oIGDJN2tidHCqYTDINVA1P1JibYX0ZY51KGmwIHj1cYFvKEiFVEGxOkBk\WyuczD1d4lv\yCdM{LQYWFVWCCjdDCxNEB2VSCjZoTldkAyOCCvaX7z M3\4dFIzOjF{N{Kx
human HCT116 cells NI\V[VdHfW6ldHnvckBie3OjeR?= Mn;QNVAh|ryP NUTrNo14UW6qaXLpeIlwdiCxZjDQTVNM[WyyaHGgbY4hcHWvYX6gTGNVOTF4IHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhSWu2IGPldlQ4OyCyaH;zdIhwenmuYYTpc44h[XRiMUCgeW0h[nliaX3teY5w[myxdDDhcoFtgXOrcx?= Mm\3NlIzOTJ5MkG=
human HCT116 cells M4\YPWZ2dmO2aX;uJIF{e2G7 NYnYPHl5OTBizszN NFTsXYtKdmirYnn0bY9vKG:oIGDJN2tidHCqYTDINVA1P1JibYX0ZY51KGmwIHj1cYFvKEiFVEGxOkBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFHreEBU\XJ2N{OgdIhwe3Cqb4L5cIF1cW:wIHH0JFExKHWPIHL5JIludXWwb3Lsc5Qh[W6jbInzbZM> NVS4[2JNOjJ{MUK3NlE>
human PC3 cells NEjNNmVHfW6ldHnvckBie3OjeR?= MV:1NEDPxE1? NEi2[JU5KGh? MmfSTY5lfWO2aX;uJI9nKHB{MTDwdo91\WmwIHX4dJJme3Orb36gbY4hcHWvYX6gVGM{KGOnbHzzJIF1KDVyIIXNJIlv[3WkYYTl[EBnd3JiODDodpMh[nliV3XzeIVzdiCkbH;0eIlv\yC{ZXzheIl3\SC2bzD1cpRz\WG2ZXSgZ49vfHKxbB?= M2\wO|IzQTl6NEey
human LNCAP cells MlfLSpVv[3Srb36gZZN{[Xl? NYPR[Gc6OC5zLUOwJO69VQ>? M1PV[VMxKG2rbh?= MliyTY5pcWKrdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIFzOR2FRKGOnbHzzJIF1KDBwMTD0c{A{OCC3TTDh[pRmeiB|MDDtbY5{KGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=> MnTNNlI5OzJ|MU[=
human LNCAP cells NXrQS4hWTnWwY4Tpc44h[XO|YYm= NVfoT21SOC5zLUOwJO69VQ>? NXXWXHk2OjRiaB?= MXfEc5dvemWpdXzheIlwdiCxZjDzeZJ3cX[rbjDlfJBz\XO|aX;uJIlvKGi3bXHuJGxPS0GSIHPlcIx{KGG2IECuNUB1dyB|MDD1UUBi\nSncjCyOEBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{ M3THOlIzQDN{M{G2
HUVEC MXPGeY5kfGmxbjDhd5NigQ>? M1yzOlExNTJ3IN88US=> MoT4NVYhcA>? MoTWTY5pcWKrdHnvckBw\iCWTl\hcJBp[S2|dHnteYxifGWmIFnDRW0uOSCvUl7BJIV5eHKnc4Ppc44hcW5iSGXWSWMh[XRiMUCgeI8hOjVidV2gdJJmfHKnYYTl[EBnd3JiMU[gbJJ{KGKnZn;y[UBVVk[jbIDoZUBkcGGubHXu[4UhdWWjc4Xy[YQh[W[2ZYKgOkBpenNiYomgVnQuWEOUIHHuZYx6e2m| NFL3dHYzOjB{NkSxNC=>
HUVEC M{jodmZ2dmO2aX;uJIF{e2G7 MX6xNE0zPSEQvF2= NYTEcotuOzBibXnu MnLrTY5pcWKrdHnvckBw\iCWTl\hcJBp[S2|dHnteYxifGWmIHj1cYFvKEmFQV2tNUBxem:vb4TldkBi[3Srdnn0fUBmgHC{ZYPz[YQhcW5iSGXWSWMh[XO|ZYPz[YQh[XNiYnX0ZU1o[WyjY4Tvd4ll[XOnIHHjeIl3cXS7IHH0JFExKHSxIEK1JJVOKHC{ZYTy[YF1\WRiZn;yJFMxKG2rboOgZoVnd3KnIGTOSoFteGijIHPoZYxt\W6pZTDt[YF{fXKnZDDh[pRmeiB3IHjyd{BjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO|YYm= MUeyNlAzPjRzMB?=
human H1299 cells NGP3cIZHfW6ldHnvckBie3OjeR?= NUTsO2pUOC5zLUOwJO69VQ>? MUmyOEBp MmTYSI94diC{ZXf1cIF1cW:wIH;mJINKSVB{IHX4dJJme3Orb36gbY4hcHWvYX6gTFEzQTliY3XscJMh[XRiMD6xJJRwKDNyIIXNJIFnfGW{IEK0JIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM> MVWyNlYzOjB4OR?=
human H1299 cells NGfjPYVHfW6ldHnvckBie3OjeR?= MlPoNE4yNTNyIN88US=> MUiyOEBp NVvjZ5pKTG:5bjDy[Yd2dGG2aX;uJI9nKGOLQWCyJIV5eHKnc4Ppc44hcW5iaIXtZY4hUDF{OUmgZ4VtdHNiYYSgNE4yKHSxIEOwJJVOKGGodHXyJFI1KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXNiaX6gdJJme2WwY3Wgc4YhOTByIIXnM41tKFSUQVnMJIFv\CCSSUPLJIlvcGmkaYTvdkBNYTJ7NECwNi=> MWCyNlYzOjB4OR?=
human H1299 cells NWfteJJvTnWwY4Tpc44h[XO|YYm= NX3jRWg5OC5zLUOwJO69VQ>? NXfPOVJwOjRiaB?= NIXtVnhKdmS3Y4Tpc44hd2ZiRGK1JIV5eHKnc4Ppc44hcW5iaIXtZY4hUDF{OUmgZ4VtdHNiYYSgNE4yKHSxIEOwJJVOKGGodHXyJFI1KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? M3vZN|IzPjJ{ME[5
human H1299 cells NFzzPIlHfW6ldHnvckBie3OjeR?= NX7UeGZoOC5zLUOwJO69VQ>? Mn74NlQhcA>? NFzBd5dKdmS3Y4Tpc44hd2ZiSl7LMY1m\GmjdHXkJGNJV1BiZYjwdoV{e2mxbjDpckBpfW2jbjDINVI6QSClZXzsd{BifCByLkGgeI8hOzBidV2gZYZ1\XJiMkSgbJJ{KGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=> M{O4OVIzPjJ{ME[5
HEK293 cells Mk\3SpVv[3Srb36gZZN{[Xl? M3T5U|EvPSCq NX3vcXlkTGm|cHzhZ4Vu\W62IH;mJHs{UF2OU1Sg[pJwdSCqdX3hckA2UFR4IILlZ4VxfG:{IHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNiYX\0[ZIhOS53IHjyd{BjgSCuaYH1bYQhe2OrboTpcIxifGmxbjDjc5VvfGmwZx?= NX;y[o51OjJ3M{exOVM>
human U251HRE cells MlPqSpVv[3Srb36gZZN{[Xl? MUjJcohq[mm2aX;uJI9nKGi7cH;4bYEucW6mdXPl[EBJUUZzIHHjeIl3[XSrb36gbY4hcHWvYX6gWVI2OUiURTDj[YxteyCkeTDj[YxtKGKjc3XkJJJmeG:{dHXyJIdmdmViYYPzZZk> NFjne3QyQDVyMU[wNS=>
human HCT116 cells MnO2SpVv[3Srb36gZZN{[Xl? MoftNVAh|ryP MlqxTY5pcWKrdHnvckBw\iCDa4Sg[ZhxemW|c3nvckBqdiCqdX3hckBJS1RzMU[gZ4VtdHNiYYSgNVAhfU1iYomgbY1ufW6xYnzveEBidmGueYPpdy=> M1zleVIzOjF{N{Kx
Sf9 cells NGrxZppndHWxcnXzZ4VvfCCyb3zhdol7[XSrb36gZZN{[Xl? MoX2TY5pcWKrdHnvckBw\iCqdX3hckBRUTONZ3HtcYEh\XiycnXzd4VlKGmwIGPmPUBk\WyuczDifUBndHWxcnXzZ4VvfCCyb3zhdol7[XSrb36gZZN{[Xl? MkPXNlEyOjF4M{G=
human HCT116 cells MVfQdo9tcW[ncnH0bY9vKGG|c3H5 MmrWO|IhcA>? NIW4SZhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJIFje2:{YnHuZ4Uh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME21NU45OiEQvF2u NWfoUWpKOjV4OUO3PFc>
human HCT116 cells NHvnXVREgXSxdH;4bYPDqGG|c3H5 M1r2TFczKGh? MVfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME21Ok4xOSEQvF2u NVXuPVFZOjF7NEWyOVA>
human PC3 cells M3jIcGN6fG:2b4jpZ:Kh[XO|YYm= NX\tRYdQPzJiaB?= MV3DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQR|Mh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD14MT6zOUDPxE1w MYiyNlQ5ODh3MR?=
human HuH7 cells NWrJS|N2WHKxbHnm[ZJifGmxbjDhd5NigQ>? NEfOPXE4OiCq NUDWU4ZRSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIeWg4KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gZYJ{d3KkYX7j[UBi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPU[3MlE5KM7:TT6= MnfjNlU3QTN5OEe=
human A549 cells MX\Qdo9tcW[ncnH0bY9vKGG|c3H5 M3vid|czKGh? MXzBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF3NEmgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCjYoPvdoJidmOnIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:QDJwM{Kg{txONg>? NGTLWoszPTZ7M{e4Oy=>
human A549 cells M3K2R2N6fG:2b4jpZ:Kh[XO|YYm= Mn3oO|IhcA>? NYfyfYE3S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6 NWHEZXQxOjJ2OEC4OVE>
human PC3 cells NVP0cJJPWHKxbHnm[ZJifGmxbjDhd5NigQ>? NEi3WHgzPSEQvF2= NVz4V2I6OTJyIHi= NILFNIFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDDN{Bk\WyuczDheEAzPSC3TTDh[pRmeiBzMkCgbJJ{KGK7IF3UWEBie3OjeTDy[YxifGm4ZTD0c{BFVVOR MYCxOlY5ODF3OR?=
human H460 cells M{PWemZ2dmO2aX;uJIF{e2G7 MnXMN|Ah|ryP M1r2e2lvcGmkaYTpc44hd2ZiUFmzT{BqdiCqdX3hckBJPDZyIHPlcIx{KGG|c3Xzd4VlKGG|IFHreEBxcG:|cHjvdplt[XSrb36gZZQhW2W{IES3N{B2eCC2bzCzNEB2VQ>? MWmxPFUxOTZyMR?=
human IGROV1 cells NWHrSlhETnWwY4Tpc44h[XO|YYm= MoLsNlQhcA>? MX;D[YxtKGO7Y3zlJIFzemW|dDDpckBpfW2jbjDJS3JQXjFiY3XscJMh[XO|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJIF1KEdzIIDoZZNmKGG2IEGg[o9t\CCLQ{WwJIFnfGW{IEK0JIhzeyCkeTDmcI94KGO7dH;t[ZRzgQ>? NX6yeoFJOjF{MU[xOVE>
human IGROV1 cells MX\GeY5kfGmxbjDhd5NigQ>? MWGyOEBp NFG0VplE\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBKT1KRVkGgZ4VtdHNiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKGG2IFexJJBp[XOnIHH0JFUh\m:uZDDJR|UxKGGodHXyJFI1KGi{czDifUBndG:5IHP5eI9u\XS{eR?= Mn\6NlEzOTZzNUG=
human H4 cells NGrGS3NHfW6ldHnvckBie3OjeR?= MXSyJIg> M{izW2Rm[3KnYYPlJIlvKE[\VlWtVmZRMyC4ZYPpZ4xmKGmwdHXud4l1gSCyZYKgZ4VtdCCrbjDoeY1idiCKNDDj[YxteyCjZoTldkAzKGi{czDy[YxifGm4ZTD0c{Bkd262cn;s NHvyOIsyQDB{NEW4OC=>
human MGC803 cells MUPGeY5kfGmxbjDhd5NigQ>? NVHJd4dsOjVizszN NVn2SmhHPDhiaB?= NULLWIFQS2WubDDjfYNt\SCjcoLld5QhcW5iaIXtZY4hVUeFOECzJINmdGy|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCjdDDHNk9OKHCqYYPlJIF1KDJ3IIXNJIFnfGW{IES4JIhzeyC3c3nu[{Bxem:yaXTpeY0hcW:maXTlJJN1[WmwaX7nJIFnfGW{IES4JIhzeyCkeTDmcI94KGO7dH;t[ZRmeiC{ZXzheIl3\SC2bzDjc451em:u M33x[|I1OTF7OE[5

多くの細胞株試験データを見る場合、クリックしてください

体内試験 LY294002 also results in suppression of tumor growth and induction of apoptosis, especially in the LoVo tumors, and therefore shows remarkable effectiveness in the mouse peritonitis carcinomatosa model. [2] LY294002 significantly inhibits growth and ascites formation of ovarian carcinoma. [3]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[4]
+ 展開

kinase assays:

PI3K inhibition by LY294002 is determined in a radiometric assay using purified, recombinant enzymes with 1 μM ATP. The kinase reaction is carried out for 1 hour at room temperature (24oC) and is terminated by addition of PBS. IC50 values are subsequently determined using a sigmoidal dose–response curve fit (variable slope). CK2 and GSK3β (glycogen synthase kinase 3β) inhibition is established by kinase selectivity screening. LY294002 is tested against the Upstate panel of kinases in 10 μM ATP.
細胞試験: [2]
+ 展開
  • 細胞株: Colon cancer cell lines DLD-1, LoVo, HCT15, and Colo205
  • 濃度: 0–50 μM
  • 反応時間: 0–48 hours
  • 実験の流れ: 1.0×105 cells (100 μL volume/well) are inoculated into 96-well microtiter plates. LY294002 is added to triplicate wells and cultured at 37oC for 0–48 hours. After treatment, 10 μL of Premix WST-1 are added to each microculture well, and the plates are incubated for 60 minutes at 37oC, after which absorbance at 450 nm is measured with a microplate reader.
    (参考用のみ)
動物試験:[3]
+ 展開
  • 動物モデル: Two groups of athymic nude mice (5–7 weeks) are inoculated i.p. with OVCAR-3 cells
  • 製剤: Dissolved in DMSO plus 0.25 ml of PBS
  • 投薬量: 0–100 mg/kg
  • 投与方法: Administered via i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 36 mg/mL (117.13 mM)
Ethanol 21 mg/mL (68.32 mM)
Water Insoluble
体内 順序で溶剤を入れること:
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 307.34
化学式

C19H17NO3

CAS No. 154447-36-6
保管
別名 SF 1101, NSC 697286

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    I want to buy a inhibitor that can inactivates Akt/PI3K. I notice the protocol of LY294002 (catalog no. s1105) says it will inactivates Akt/PKB. Is LY294002 available for Akt/PI3K inhibition?

  • 回答:

    LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively. It can inhibit PI3K/AKT. PKB is the alternative name of AKT.

  • 問題2:

    What is the suggested formulation of this compound for mouse injection(i.p.)?

  • 回答:

    It can be dissolved in 4% DMSO/30% PEG 300/5% Tween 80/ddH2O at 5 mg/ml clearly, and the concentration of DMSO is safe for in vivo experiments.

Related Antibodies

PI3K信号経路図

PI3K Inhibitors with Unique Features

相関PI3K製品

Tags: LY294002を買う | LY294002 ic50 | LY294002供給者 | LY294002を購入する | LY294002費用 | LY294002生産者 | オーダーLY294002 | LY294002化学構造 | LY294002分子量 | LY294002代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID